Effectiveness of Complex Treatment of Patients with Chronic Heart Failure Taking into Account Immune System Condition

In order to evaluate glutargin and imunofan efficiency the changes of clinical manifestations and parameters of cellular and humoral immunity, oxidation-reduction processes, metabolic intoxication depending on CHF stage were studied in 96 patients suffering from arterial hypertension with chronic heart failure (CHF). Secondary immunodeficiency, activation of lipid peroxidation and metabolic intoxication increasing with CHF stage developed in patients with FC III CHF at stage II A and FC IV at stage II B according to NYHA. The use of glutargin and imunofan in complex treatment of the patients with CHF improves the effectiveness of treatment, the cellular and humoral immunity indices, reduces secondary immunodeficiency and metabolic intoxication.